Indian Drugmaker Receives Import Ban After Drug Shortage Ends

International Pharmaceutical Regulatory Monitor
A A
The FDA has broadened its import ban against Indian manufacturer Ipca Laboratories to include four drugs previously exempted due to shortage. Only Ipca’s anti-malarial API remains exempted and can be imported into the U.S.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor